Compare · AIKI vs NPT
AIKI vs NPT
Side-by-side comparison of AIkido Pharma Inc. (AIKI) and Texxon Holding Limited (NPT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AIKI and NPT operate in Specialty Chemicals (Consumer Discretionary), so they compete in similar markets.
- NPT carries a market cap of $35.5M.
- NPT has hit the wire 2 times in the past 4 weeks while AIKI has been quiet.
- AIKI has more recent analyst coverage (1 ratings vs 0 for NPT).
- Company
- AIkido Pharma Inc.
- Texxon Holding Limited
- Price
- -
- -
- Market cap
- -
- $35.5M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Specialty Chemicals
- Specialty Chemicals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- News (4w)
- 0
- 2
- Recent ratings
- 1
- 0
AIkido Pharma Inc.
AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. Its pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The Company is also developing an antiviral platform that inhibits replication of multiple viruses, including influenza virus, SARS-CoV, MERS-CoV, Ebolavirus, and Marburg virus. It has a license agreement with the University of Texas; and Wake Forest University Health Sciences. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2021. AIkido Pharma Inc. was founded in 1967 and is based in New York, New York.
Latest AIKI
- SEC Form SC 13D filed by AIkido Pharma Inc.
- SEC Form SC 13D/A filed by AIkido Pharma Inc. (Amendment)
- Wool Kyle Michael bought $12,996 worth of shares (5,000 units at $2.60) (SEC Form 4)
- Devall Christopher Franklin bought $17,863 worth of shares (7,000 units at $2.55), increasing direct ownership by 30% to 30,033 units (SEC Form 4)
- Wool Kyle Michael was granted 630,050 shares, increasing direct ownership by 77% to 1,448,908 units (SEC Form 4)
- Hayes Anthony bought $140,168 worth of shares (70,000 units at $2.00) (SEC Form 4)
- AIkido Pharma Inc. filed SEC Form 8-K: Leadership Update
- Hayes Anthony bought $8,012 worth of shares (4,000 units at $2.00) (SEC Form 4)
- Wool Kyle Michael bought $8,122 worth of shares (4,000 units at $2.03) (SEC Form 4)
- Devall Christopher Franklin bought $2,278 worth of shares (1,000 units at $2.28), increasing direct ownership by 5% to 23,033 units (SEC Form 4)
Latest NPT
- Texxon Holding Limited Announces Financial Results for Fiscal Year 2026
- SEC Form NT 20-F filed by Texxon Holding Limited
- Texxon Holding Limited Announces Commencement of Operations at Henan Polystyrene Production Facility, A Milestone in Manufacturing Expansion Strategy
- SEC Form 6-K filed by Texxon Holding Limited
- Texxon Holding Limited Announces Unaudited Financial Results for the First Half of Fiscal Year 2026
- SEC Form 6-K filed by Texxon Holding Limited
- SEC Form 6-K filed by Texxon Holding Limited
- Texxon Holding Limited Announces Annual General Meeting
- SEC Form 3 filed by new insider Xu Hui
- SEC Form 3 filed by new insider Huang Jian (Hanke)